Clinical trials: Standard Therapy
HIV Infections, Tuberculosis
Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
The investigators propose to conduct a phase 2 randomised (1:1) double-blind placebo-controlled trial of the dolutegravir-lamivudine-tenofovir fixed dose combination tablet daily with an additional 50 mg dose of…
- Trial name
- RADIANT-TB (NCT03851588)
- Testing
- Dolutegravir 50 mg
- Where
- South Africa
- Volunteers
- 108 people
- Sponsor
- University of Cape Town
Renal Cell Carcinoma
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
This study is a multicenter, non-interventional, retrospective, medical chart review of participants with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December…
- Trial name
- NCT05650164
- Testing
- avelumab, axitinib
- Where
- 19 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Helicobacter Pylori Infection
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
A phase 4 prospective, randomized, open-label clinical trial evaluating the efficacy of high dose dual therapy vs standard triple therapy in a diverse, urban New York City population.
- Trial name
- NCT05342532
- Testing
- Amoxicillin, Omeprazole, Clarithromycin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Myeloma
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this phase 1/2, open-label study was to evaluate the effect of oral formulation of Ixazomib when added to standard melphalan and prednisone (MP) treatment.
- Trial name
- NCT01335685
- Testing
- Ixazomib, Melphalan, Prednisone
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Urinary Bladder Neoplasms
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
- Trial name
- CheckMate 7G8 (NCT04149574)
- Testing
- nivolumab, Bacillus Calmette-Guérin (BCG)
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Wound of Knee, Wound of Hip
Study to Compare Negative Pressure Wound Therapy or Standard Dressings After Orthopedic Surgery
The aim of this study is to assess the prevention of incision healing complications in patients undergoing Total Knee Arthroscopy (TKA) and Total Hip Arthroscopy (THA) treated with either Single-Use Incisional NPWT (Negative…
- Trial name
- PICO (NCT02064270)
- Testing
- Single-Use Negative Pressure Wound Therapy, Standard postsurgical dressings
- Where
- United States
- Volunteers
- 526 people
- Sponsor
- University of Missouri-Columbia
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with…
- Trial name
- NCT01227707
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], Radiation therapy
- Where
- 9 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
- Trial name
- NCT00130728
- Testing
- bevacizumab, erlotinib HCl
- Where
- 4 sites in United States
- Volunteers
- 636 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin…
- Trial name
- NCT04907539
- Testing
- RXC004, Nivolumab, Denosumab
- Where
- 22 sites in United States, South Korea and 2 more
- Volunteers
- 25 people
- Sponsor
- Redx Pharma Ltd
Carcinoma, Renal Cell
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
The purpose of the study is to: Find out if patients receiving BAY43-9006 will live longer without tumor progression than those receiving standard therapy with interferon alpha-2a Find out if a higher dose of BAY43-9006 can…
- Trial name
- NCT00117637
- Testing
- Sorafenib (Nexavar, BAY43-9006), Interferon
- Where
- 42 sites in United States, France and 5 more
- Volunteers
- 189 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Bone Metastases
A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
The goal of this clinical research study is to learn if 1 large dose of radiation therapy is better at controlling pain from cancer that has spread to the bones than 10 smaller doses of radiation.
- Trial name
- NCT02163226
- Testing
- Hypofractionated Radiation Treatment, One Radiation Treatment, Questionnaire
- Where
- 3 sites in United States
- Volunteers
- 167 people
- Sponsor
- M.D. Anderson Cancer Center
Stable Angina
Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
In this study the investigators will use careful scientific blinding of patient and their subsequent healthcare staff so that the investigators can determine exactly how much difference coronary angioplasty makes to symptoms and…
- Trial name
- ORBITA (NCT02062593)
- Testing
- Coronary angioplasty
- Where
- 5 sites in United Kingdom
- Volunteers
- 230 people
- Sponsor
- Imperial College London
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- FLAURA (NCT02296125)
- Testing
- Erlotinib 150/100 mg, Gefitinib 250 mg
- Where
- 170 sites in United States, Australia and 28 more
- Volunteers
- 674 people
- Sponsor
- AstraZeneca
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
Covid19
COVID-19 Study of Safety and Tolerability of Alvelestat
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK), and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase inhibitor) orally twice per day for 10 days…
- Trial name
- COSTA (NCT04539795)
- Testing
- Alvelestat
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Neovascular Age-related Macular Degeneration, Retinal Disease
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
This study is designed to investigate the safety and tolerability of GEM103 IVT injection + standard of care vs. sham + standard of care.
- Conditions
- Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
- Trial name
- NCT04684394
- Testing
- GEM103, Aflibercept
- Where
- 23 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gemini Therapeutics, Inc.